ArticleJournal of veterinary science2025
Baicalin confers neuroprotection in animal models of stroke through its antioxidant and anti-apoptotic effects.
Article in Journal of veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Baicalin ameliorates podocyte injury and renal function impairment in idiopathic membranous nephropathy by inhibiting the AGE/RAGE signaling.Renal failure · 2026Article
- Baicalin and CNS-related diseases: new insights into neuroprotective potentials based on underlying mechanisms.Biochemistry and biophysics reports · 2026Review
- Baicalin modulates metabolic and inflammatory proteins and attenuates neuronal damage in a rat model of ischemic stroke.Journal of veterinary science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
importanceIschemic stroke leads to neuronal cell death due to a lack of oxygen and glucose. Baicalin is a flavonoid that has antioxidant and anti-inflammatory properties.
objectiveThe aim of this study is to elucidate the anti-oxidant and anti-apoptotic effects of baicalin in animal models of stroke.
methodsVehicle or baicalin (100 mg/kg) was administered intraperitoneally immediately after the middle cerebral artery occlusion (MCAO) surgery. Neurobehavioral tests were conducted 24 h post-MCAO and brain tissue was isolated to assess histopathological changes and apoptosis-associated protein expression. Additionally, reactive oxygen species (ROS) and lipid peroxidation (LPO) assays were performed to evaluate oxidative stress.
resultsMCAO animals exhibited severe neurological deficits, which were significantly alleviated by baicalin treatment. Baicalin mitigated the up-regulation in ROS and LPO levels induced by surgery. MCAO damage led to severe histopathological lesions and an increase in terminal deoxynucleotidyl transferase dUTP nick end labeling-positive reactions, these alterations were alleviated by baicalin treatment. MCAO damage decreases the expression of Bcl-2 and increases the expression of Bax, baicalin alleviates these changes. Baicalin also attenuated the upregulation of caspase-3 expression caused by MCAO injury. CONCLUSIONS AND RELEVANCE: These results can suggest evidence that baicalin exerts neuroprotective effects by preventing apoptosis during cerebral ischemia. In conclusion, baicalin acts as a potent neuroprotective agent through its antioxidant and anti-apoptotic effects on neuronal cell damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.